| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.12B | +35.0% |
| Gross profit | ¥0.03B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | -32.1% |
| Gross margin | 22.5% | Net margin 15.9% |
| Revenue Q/Q | +79.9% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 77.5% |
| R&D | ¥0.00B | 3.4% |
| SG&A | ¥0.01B | 5.6% |
| Tax & other | ¥0.00B | 2.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技 ・ 中汽股份 ・ 万凯新材 ・ 铜冠铜箔
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies